1. Home
  2. ETG vs IMCR Comparison

ETG vs IMCR Comparison

Compare ETG & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eaton Vance Tax-Advantaged Global Dividend Income Fund of Beneficial Interest

ETG

Eaton Vance Tax-Advantaged Global Dividend Income Fund of Beneficial Interest

HOLD

Current Price

$23.29

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$34.05

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ETG
IMCR
Founded
N/A
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
2003
2016

Fundamental Metrics

Financial Performance
Metric
ETG
IMCR
Price
$23.29
$34.05
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$66.33
AVG Volume (30 Days)
85.9K
347.6K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.39
EPS
N/A
0.23
Revenue
N/A
$249,428,000.00
Revenue This Year
N/A
$14.57
Revenue Next Year
N/A
$8.21
P/E Ratio
N/A
$149.87
Revenue Growth
N/A
43.05
52 Week Low
$19.34
$27.56
52 Week High
$24.71
$40.71

Technical Indicators

Market Signals
Indicator
ETG
IMCR
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
ETG
IMCR

About ETG Eaton Vance Tax-Advantaged Global Dividend Income Fund of Beneficial Interest

Eaton Vance Tax Advgd Gbl Div Inc Fd is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of aerospace and defense, capital markets, diversified telecommunication services, electrical equipment, biotechnology, banks, and other areas.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: